Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Versicor (VERS) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (40)	3/17/2003 11:22:30 PM
From: JOEBT1	Read Replies (1) \| Respond to of 83

Texas Dude--Thank you. I listened to the conference call and they said the same thing as the Dietz comments. In the call they said that the recurrence difference was irrelevant since they would maintain treatment in the real world as compared to the trial. I suspect it will be down somewhat even though the news is as good as could be expected. The analysts seem to be satisfied with the answers given during the conference call. Joe

To: Arthur Radley who wrote (40)	3/30/2003 12:34:49 PM
From: tuck	Read Replies (2) \| Respond to of 83

Thought folks might like to know BioSpace's Dr. Garren likes VERS -- now MICU, having changed its name to Viculon (why? many feel name changes are a red flag, our esteemed Peter among them): biospace.com He comes to the same conclusions about the PIII results that we have. The follow-up data is immaterial to the main indications MICU is going after. He also notes Fujisawa's drug is on the same timeline now that the FDA has asked for more data. Cheers, Tuck